西班牙内分泌学会（SEEN）甲状腺癌工作组和西班牙罕见及孤儿肿瘤特别工作组就晚期甲状腺髓样癌的管理达成的共识
Consensus on the management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI).
作者信息
Galofré Juan C, Santamaría Sandi Javier, Capdevila Jaume, Navarro González Elena, Zafón Llopis Carles, Ramón Y Cajal Asensio Teresa, Gómez Sáez José Manuel, Jiménez-Fonseca Paula, Riesco Eizaguirre Garcilaso, Grande Enrique
机构信息
Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pamplona, Spain.
Service of Endocrinology and Nutrition, Hospital Universitario de Cruces, Vizcaya, Spain.
出版信息
Endocrinol Nutr. 2015 Apr;62(4):e37-46. doi: 10.1016/j.endonu.2015.01.005. Epub 2015 Feb 26.
BACKGROUND
In Spain medullary thyroid carcinoma (MTC) would not exceed 80 new cases per year and less than half of them would be good candidates for systemic treatment with novel agents.
METHODS
Relevant literature was reviewed, including PubMed searches supplemented with additional articles.
RESULTS
The consensus summarizes the clinical outcomes in terms of activity and toxicity of each of the available drugs. A brief summary of the minimum requirements in terms of follow up and genetic counseling around MTC is also included.
CONCLUSIONS
Only those patients with objective imaging progression in the last 12-14 months with large volume of disease are clear candidates to start systemic treatment. However, those patients with low disease volume should be considered for 'wait and see' strategy until symptoms of the disease appear. Multidisciplinary approach for the management of MTC patient is mandatory nowadays.
背景
在西班牙，每年甲状腺髓样癌（MTC）新发病例不超过80例，其中不到一半的患者是新型药物全身治疗的合适人选。
方法
对相关文献进行了综述，包括通过PubMed检索并补充其他文章。
结果
该共识总结了每种可用药物在活性和毒性方面的临床结果。还包括了关于MTC随访和遗传咨询最低要求的简要总结。
结论
只有那些在过去12至14个月内有客观影像学进展且疾病负荷大的患者才是开始全身治疗的明确人选。然而，那些疾病负荷低的患者应考虑采用“观察等待”策略，直到出现疾病症状。如今，对MTC患者进行多学科管理是必不可少的。
Zotero 插件